All BullZZ no BearZZ!

[InvestorSuisse]

AEterna Zentaris (AEZS) is a undiscovered biotech company with multiple pahse III,
phase II, phase I and several promising preclinical cancer drugs. They have almost
no debt ($300k), $40mln cash, only 115mln mcap with low $6 mln cash burn.

Over 45% of shares are held by institutions/mutal funds and insiders:
http://www.dailyfinance.com/company/aete...

Recently published article, AEZS - Uncovering the next dominant cancer company
http://www.themarketfinancial.com/aetern...

Do your own DD. Link to latest AEteran presentation from May 2010:
http://www.aeternazentaris.com/pdfdyn/Pr...

Check out AEterna's pipeline of drugs:
http://www.aeternazentaris.com/en/page.p...


Perifosine, first-in-class oral AKT inhibitor
Multiple Myeloma (phase III)
Advanced Colorectal Cancer ( phase III to start soon)
Kidney Cancer (phase II)
and Others
/ AEZS licensed N.American rights to KERX, which pays for trials costs and 11% royalties
of potential futures sales. AEZS is holding the rights for rest of world, wich is as big
as north american market excluding South-Korea.

AEZS-108
Endometrial Cancer (phase II, final results end of 2010)
Ovarian Cancer (phase II, final results end of 2010)
Bladder Cancer (phase II start end of 2010)
Other Cancers

AEZS-112 (phase I)
Solid Tumor

AEZS-120 *Tumor Vaccine, (pre-clinical), phase I start in mid to second half of 2010
/ similar to DNDN's Provenge
Prostate Cancer

AEZS-129/131PI3K/ErkInhibitor (pre-clinical)
/ Similar to Ariads ridaforolimus, licensed to Merck for up to $500mln


AEZS-127 Intravenous administrionable Perifosine
And here is AEZS masterplan:

Once KERX does pays all the trials for Perifosine and the drug succeeds, AEZS will present
Perifosine II, intravenous injectable and thus very likely more efficient Perifosine:

AEZS-127 (Erucylphosphocholine (ErPC)) is an analog of perifosine which is suitable for
intravenous administration. Like perifosine, AEZS-127 belongs to a new class of compounds
based on alkylphosphocholines that Æterna Zentaris has developed in our Drug Discovery group.
AEZS-127 possesses distinctive reduced hemolytic activity thus allowing for intravenous injection.
Æterna Zentaris owns the worldwide rights.



Cetrotide®
(Marketed by Merck Serono, Nippon Kayaku / Shionogi (Japan))
In VitroFertilization, AEterna gets around $6 mln per quarter

AEZS-130 (SolorelTM)
Diagnostic – Adult Growth Hormone Deficiency, phase III

AEZS-130 has shown to stimulate appetite and therefore could be used to treat cachexia,
a condition which results in a severe reduction of muscle mass and weight loss in
patients suffering from conditions such as chronic obstructive pulmonary disease, AIDS
and certain cancers. Potential update in 2010.

AEZS-130 (macimorelin) - Phase I
Therapeutic

AEZS-123Ghrelin Antagonist - Preclinical
EndocrinologyPartners:



Because of incredible low valuation, AEZS is listed as top acquisition target:

http://finance.yahoo.com/news/Brean-Murr... xpert-twst-1880440369.html?x=0&.v=1
http://finance.yahoo.com/news/60-Premium...

Mootley Fool says, a buyout and bidding war could indeed come:
http://www.fool.com/investing/high-growt...


IMO, based on AEterna's great pipeline of late stage cancer drugs, she should be trading
well over $8 and could be taken over for $15 per share. I think, AEZS is a multi-bagger
and worth doing your own DD. If there's no buyout and Perifosine is marketed, AEZS could
be a 100-bagger, a 10.000% chance.